PPT-Proceedings of the SAGE Working Group on Rubella Vaccines

Susan E Reef MD Global Measles and Rubella Management Meeting March 15 2011 Outline Background Terms of Reference Opportunities to align with measles strategies Recommendations from the WG. Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Regional MR TAG . Nairobi, Kenya . June 2-3 , 2015 . Outline . Background . Epidemiology of Rubella . Strategic options for rubella control AFR . MR introduction progress noted issues related to MR introduction in AFR . 10. th. Measles Initiative Meeting. September 13-14, 2011, . Washington DC. Susan. E. Reef, CDC/GID/DEEB. Peter M. Strebel, WHO/HQ/IVB/EPI. Outline. Global and regional status . CRS burden. Vaccine uptake and regional goals. Surveillance and Control . in . Low. -Resource Settings: . Limitations. , Biases, and . Potential . for Strengthening. Amy Winter, PhD Candidate, Princeton University. Advisor:. Jess Metcalf. Assistant Professor of Ecology and . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Accelerating progress towards measles and rubella elimination. Geneva, Switzerland 21-23 June 2016 . Jenny Rota, WHO consultant. Goal is to update information to reflect current responsibilities of the network, provide best practices, resources and guidelines. South East Asia Region. 1. 21 June 2016. Geneva, Switzerland. Regional Measles and Rubella Goals. 66th Meeting of the SEAR Regional Committee in September 2013 in New Delhi resolved . to adopt . the goal of . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Measles and Rubella Annual Partners Meeting, September 15-16 2015. Background. The MRI FRR is developed by the M&RI FRR/RMAWG. Country population data is drawn from UNDP estimates. Vaccine type and timing of SIAs is from countries . Appendix 17 Date of Report: Month Day Year Date of last Evaluation of Infant: Month Day Year l PATIENT INFORMATION Child’s Name: La MEA R) VACCINE What is the measles, mump and rubella (MMR) vaccine? The MMR vaccine protects against three diseases: measles, mumps and rubella (german measles). The vaccine is approved by He alth C ALL students are REQUIRED to provide proof of immunity to measles, mumps, and rubella (“MMR”). Before students may enroll in classes, NAU requires documentation of ONE of the following: • Tw pregnancy What you need to know What is Rubella (German measles)? Rubella is a contagious disease caused by a virus. How is it spread? Rubella is spread by close contact with an infected person, th David Dahlgren, . Lorien. Belton, and Terry Messmer. Utah State University. www.utahcbcp.org. If its not good for communities, its not good for wildlife. .. Departments of the Interior, Agriculture, Commerce, and Defense and the Environmental Protection Agency.